Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises A3P Biomedical in conjunction with directed share issue
Mandate

Vinge advises A3P Biomedical in conjunction with directed share issue

May 05, 2022 M&A

Vinge has advised A3P Biomedical in connection with an issue of shares amounting to SEK 400 million directed at Stena Sessan AB, TomEqt Private AB, Flerie Invest AB, Östersjöstiftelsen and Inbox Capital. A3P Biomedical specialises in advanced diagnostics of prostate cancer.

Vinge’s team primarily consisted of Johan Winnerblad, Rikard Lindahl, William Kåge, Lorin Arabi, Gabriel Chabo, Stojan Arnerstål, Arvid Axelryd and Olivia Belding.

Related

Vinge advises Summit Partners on its $1 billion-plus investment in Keyfactor

 Vinge has, together with Kirkland & Ellis, advised Summit Partners in connection with a strategic growth investment in Keyfactor, a leader in trust infrastructure. The investment will help accelerate the company's global scale and growth initiatives, enabling product innovation, geographic expansion, team building and strategic acquisitions.
July 20, 2026

Vinge has advised VAROPreem in connection with its acquisition of Sunpine

 Vinge has advised VAROPreem in connection with its acquisition of Sunpine from Sveaskog, Södra Skogsägarna and Lawter.
July 10, 2026

Vinge advises Consolid Equity in connection with the establishment of Petra Group

 Vinge has advised Consolid Equity Investment AB ("Consolid Equity") on the acquisition of Ström & Gulliksson, one of the leading patent agencies in the Nordics. The acquisition forms part of the establishment of Petra Group, a European platform aimed at consolidating patent agencies across Europe to combine expertise and resources primarily within patents and trademarks. Consolid acts as a strategic partner in the new group.
July 08, 2026